Login to Your Account



Foghorn funded to sound out gene control tech with $50M from Flagship

By Michael Fitzhugh
Staff Writer

Thursday, March 15, 2018

Foghorn Therapeutics Inc., a Cambridge, Mass.-based startup devoted to developing new cancer drugs that exploit the chromatin regulatory system to direct gene expression, has launched with an initial capital commitment of $50 million from Flagship Pioneering, the 17-year-old venture firm previously known as Flagship Ventures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription